26 results about "Granulocyte" patented technology

This invention relates to the fields of biomedical technology and biological model construction technology, and discloses an ANCA-associated vasculitis glomerular endothelial cell injury model, its construction method and application, and the application of BACH1 inhibitors. The method includes: (1) activating neutrophils sequentially with tumor necrosis factor α and immunoglobulin G to obtain a culture medium containing activated neutrophils; wherein the immunoglobulin G is immunoglobulin G isolated and purified from the plasma of patients with ANCA-associated vasculitis; (2) co-culturing the culture medium containing activated neutrophils with human glomerular endothelial cells to obtain the cell injury model. The cell injury model provided by this invention can verify the role of neutrophil adhesion characteristics in endothelial cell injury, and at the same time, the cell injury model can better simulate the immune microenvironment of ANCA-associated vasculitis glomerular endothelial cells in vivo.

This invention relates to an efficient particle sphere generation method based on principal component analysis (PCA), belonging to the field of quantum computing. It solves the problem of low data representation efficiency caused by excessive segmentation and noise sensitivity in existing particle sphere algorithms. The technical solution includes: initializing the particle sphere set using a parallel sampling strategy; calculating the splitting gain and setting a threshold; calculating the optimal splitting direction based on the PCA core sample set; splitting the particle spheres along the principal direction and iteratively updating the set. This method achieves efficient data compression, reduces computational complexity, enhances the representation ability of complex geometric structures, and has strong robustness.

This application belongs to the field of microbial technology, and mainly relates to a strain of *Pediococcus lactis* BPA03 and its applications. *Pediococcus lactis* BPA03 is classified and named *Pediococcus lactis*. Pediococcus acidilactici This *Pediococcus lactis* strain BPA03 was deposited on September 28, 2025, at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 36109. It inhibits skin melanin deposition and improves UV photoaging, suppresses the gene expression levels of immune factors such as IL-1β, IL-6, IL-8, and TNF-α, improves the activities of superoxide dismutase, catalase, and glutathione peroxidase, inhibits vinorelbine-induced neutropenia, and improves the inhibition of immune factor expression induced by vinorelbine, thus exhibiting comprehensive anti-aging effects.

This disclosure generally relates to compounds, compositions, and methods for treating various diseases and conditions using therapeutically effective amounts of compounds of formula (I) or formula (II), pharmaceutically acceptable salts thereof, or derivatives thereof. This disclosure generally relates to compounds, compositions, and methods for treating various diseases and conditions, and more specifically, for treating fibrosis and atopic dermatitis (AD), as well as various other diseases and conditions related to neutrophil migration. Embodiments described herein relate to compounds, compositions, and methods for treating and / or preventing fibrosis and various fibrous diseases, disorders, or conditions. TIFF2026521119000072.tif43165

This invention discloses an antimicrobial peptide, its pharmaceutical composition, and its applications. The invention optimizes the structure of the antimicrobial peptide through deuteration modification technology, significantly enhancing its targeted binding ability to β-1,3-D-glucan synthase. The affinity of this antimicrobial peptide for the aforementioned target is 9-27 times that of the control peptide. In vitro assays show that its minimum inhibitory concentration (MIC) against nine standard Candida strains is consistently 0.002 μg / mL, exhibiting significantly superior activity compared to fluconazole, anidoxurine, and the control peptide. It also exhibits extremely low cytotoxicity against L02 human normal hepatocytes. In in vivo experiments, in a neutropenic mouse model of Candida albicans infection, the antimicrobial peptide at all doses showed superior reduction in renal fungal load compared to anidoxurine and the control peptide. The antimicrobial peptide of this invention combines highly efficient anti-Candida activity, low cytotoxicity, and excellent in vivo efficacy, providing a safe and effective candidate drug for the treatment of drug-resistant candidiasis and possessing good clinical translational value.

The application provides a granulocyte-guided double-space semantic calibration clustering method for diabetic retinopathy, comprising the following steps: step 1, designing an independent encoder to extract view-specific features; step 2, performing view quality evaluation on the view-specific embedding features output by each independent encoder, and calculating the confidence weight of each view; step 3, realizing double-space collaborative semantic calibration in the feature space and the clustering space; step 4, dividing the lesion semantic unit of diabetic retinopathy through granulocyte pre-modeling, and screening an initial clustering center from high-confidence granulocytes; and step 5, dynamically adjusting the exploration, utilization strategy and clustering center update step length based on the granulocyte confidence, and combining the semantic calibration signal to realize adaptive clustering optimization. The method helps to improve the accuracy and consistency of the double-view image staging clustering of diabetic retinopathy, and significantly reduces the early lesion missed diagnosis rate and the medium-term staging confusion rate.

This invention belongs to the field of pharmaceutical technology. Addressing the problem that current TCM treatments for allergic rhinitis-asthma syndrome primarily rely on literature review and the experience of renowned practitioners, lacking clinically validated and fixed-composition TCM formulas, this invention proposes a TCM composition, a TCM preparation, its preparation method, and its application. The TCM composition provided by this invention is made from the following raw materials in parts by weight: Bupleurum chinense 3-10 parts, Angelica sinensis 6-15 parts, Paeonia lactiflora 6-15 parts, Magnolia biondii 6-15 parts, Cicadae periostracum 3-12 parts, Perilla frutescens 6-15 parts, Citrus reticulata 6-15 parts, Fritillaria cirrhosa 2-10 parts, Astragalus membranaceus 10-30 parts, Atractylodes macrocephala 10-30 parts, Saposhnikovia divaricata 6-12 parts, and Glycyrrhiza uralensis 3-12 parts. This invention can effectively improve the disease control level of CARAS patients, increase asthma control test scores, significantly reduce allergic rhinitis control symptom scores, significantly improve quality of life, and significantly alleviate clinical symptoms. Specifically, it promotes the recovery of disease and lung function by regulating immunity, increasing IFN-γ levels, reducing eosinophil infiltration, and improving chronic airway inflammation.

This invention relates to the application of a melanin-catalase nanocomposite (MAC) targeting intestinal mucosal neutrophils in the preparation of drugs for treating inflammatory bowel disease, belonging to the field of novel applications of nanomedicine. It addresses the challenges of catalase oral delivery being easily degraded and inactivated by gastrointestinal proteases and difficult to precisely target neutrophils. This invention is the first to discover a MAC prepared by in-situ polymerization of dopamine on the surface of catalase, which can be used for the treatment of inflammatory bowel disease. This nanocomposite, through oral delivery, precisely targets intestinal mucosal infiltrating neutrophils and maintains structural stability in the gastrointestinal fluid environment, effectively protecting catalase activity. It actively targets intestinal mucosal infiltrating neutrophils through the high affinity of melanin for dopamine D2 receptors, synergistically exerting a triple effect of hydrogen peroxide decomposition, hypochlorous acid scavenging, and iron ion chelation, effectively inhibiting the formation of extracellular traps in neutrophils.

This invention discloses a rifaximin nanoemulsion, its preparation method, and its application, belonging to the field of veterinary drug technology. The technical solution includes a rifaximin nanoemulsion comprising rifaximin, a compound essential oil, a surfactant, a co-surfactant, and water; the compound essential oil includes oregano oil, cinnamon oil, and tea tree oil. This invention prepares a rifaximin nanoemulsion using a compound of oregano, cinnamon, and tea tree oils as the oil phase, exhibiting both high antibacterial efficiency and high safety. The three essential oils have a synergistic antibacterial effect, complementing rifaximin through multi-target action, broadening the antibacterial spectrum, and showing significant inhibitory effects against various bacteria and fungi. It can enhance uterine smooth muscle contraction function by stimulating the synthesis and secretion of prostaglandins and oxytocin, providing potential support for uterine involution and endometrial repair. After administration, it can effectively reduce the number of inflammatory cells such as leukocytes and neutrophils in experimental dairy cows, significantly reduce purulent vaginal discharge, and restore the softness and elasticity of the uterus upon rectal examination.

Provided herein are compounds of Formula (I-A), or salts thereof, including any isomer of the above, wherein the variables are as defined herein. Such compounds can be useful in methods of treating an eosinophilic condition, disease, or disorder. Such compounds can be administered orally. Compositions described herein can be used to reduce eosinophil effector function.

The present application relates to the technical field of medical quality control products, in particular to a quality control substance for lymphocyte subset analysis and a preparation method thereof, comprising human monocyte simulation particles, human granulocyte simulation particles, human lymphocyte simulation particles, human red blood cell simulation particles, human platelet simulation particles and a preservative, wherein the human monocyte simulation particles, the human granulocyte simulation particles, the human lymphocyte simulation particles, the human red blood cell simulation particles and the human platelet simulation particles are added into the preservative, and mixed according to the concentration of human particles to obtain the quality control substance for lymphocyte subset analysis. Compared with the prior art, the quality control substance for lymphocyte subset analysis and the preparation method thereof have the advantages of simple operation, small batch difference and good stability, and can be applied to the field of quality control of flow cytometry methodological lymphocyte subset analysis.

Sickle cell disease (SCD) is a single gene disorder characterized by mutant hemoglobin-S (HbS) and chronic intravascular haemolysis. Painful vaso-occlusive crises (VOC) are typical of SCD and often associated to a further rise in hemolysis. VOC is the clinically painful form of vaso-occlusion, that is due to the aggregation of red blood cells in the capillaries and venules. Such event is promoted or aggravated by adhesion of polymorphonuclear neutrophils (PMNs) to red blood cells and the endothelium leading to tissue ischemia, inflammation and imperfect repair. Repeated vaso-occlusion and PMNs interactions with the vascular endothelium are thought to promote microvascular injuries in SCD patients. The inventors tested the effect of pharmacological inhibition of TREM-1 with LR12 peptide in two experimental vaso-occlusive crisis models. Additional validation of TREM-1 involvement in vaso-occlusion was verified using mice with sickle cell disease and Trem-1 gene deficiency. In particular, the inventors showed that TREM-1 inhibition is particular suitable for limiting the severity of vaso-occlusions. The results obtained by the inventors also suggest that plasmatic concentration of sTREM-1 could be a reliable biomarker for predicting vaso-occlusions and / or SCD-associated organ dysfunction and end-organ damage.

This invention discloses a predictive model for early fever and infection after CAR-T therapy. The equation for this predictive model is: P = 1 / (1 + e^(-3.23 + 0.017 × CRP + 0.003 × IL - 6 - 0.023 × platelet count - 8.048 × lymphocyte count - 1.241 × FCV + 1.6146 × neutropenia grade)); where P is the probability of infection. P < 0.20 is defined as low risk, classified as CRS; 0.2 ≤ P ≤ 0.6 is defined as medium risk, requiring further testing to determine whether it is infection or CRS; P > 0.6 is defined as high risk, classified as infection. This predictive model is used to predict the likelihood of infection in the first fever event after CAR-T therapy. By analyzing various clinical laboratory indicators and combining logistic regression analysis, the model screens out key predictive factors related to infection risk, ultimately establishing an efficient and easy-to-use predictive tool. This model can effectively predict the occurrence of infection, provide clinicians with guidance for early intervention, reduce unnecessary clinical testing, and optimize patients' treatment plans.

There is provided a method of identifying a neutrophil progenitor, the method comprising: determining an expression of at least one biomarker selected from the group consisting of: CD71, LOX-1, CD164, CD112, CD181, TACSTD2, CD11b and CD49d in a cell. In various embodiments, the cell is identified as a neutrophil progenitor when it is determined to have at least one of the following expression profiles: CD71hi / +, LOX-1int / lo / −, CD164hi / +, CD112hi / +, CD181int / lo / −, TACSTD2hi / +, CD11blo / − and / or CD49dint / hi / +. Also disclosed are a method of sorting and / or separating neutrophil progenitors from a cell population, a composition that is enriched in neutrophil progenitors and related uses and methods.

This invention designs an image classification method based on machine learning and spectral clustering of grains, comprising: acquiring an image dataset; extracting the feature vector of each image in the image dataset using a feature extraction model; creating an initial grain as a whole by treating the feature vectors of all images in the image dataset, and calculating the variable sparsity measure (VSM) value of the initial grain; if the VSM value is lower than a preset threshold, dividing the grain into two smaller grains using a 2-means clustering algorithm; continuing until the VSM values ​​of all grains meet the condition; calculating the similarity between the generated grains based on the center feature vector and the radius of the grains; dividing the generated grains into multiple clusters using spectral clustering based on the similarity between the grains, where each cluster represents a category; calculating the similarity between the feature vector of the image sample to be tested and the center feature vector of each grain, and taking the category corresponding to the cluster of the most similar grain as the classification result of the image sample to be tested. This invention provides more reliable and efficient technical support for the field of image classification.

The present disclosure relates to methods of treating severe asthma in a subject using compounds that bind to CD131 and inhibit signalling of interleukin (IL) 5 and granulocyte-macrophage colony stimulating factor (GM-CSF).

The present invention aims to develop a technique for measuring neutrophil counts using small amounts of blood, such as 1 μL or less, as obtained by fingertip puncture. [Solution] A method for measuring the number of neutrophils in a blood sample is provided, which includes measuring superoxide anions in the presence of bortezomib or ixazomib or a salt thereof.

Disclosed are methods of diagnosing and treating a subject with active or inactive eosinophilic esophagitis (EoE). The methods may include the steps of detecting whether a level of one or more immunoglobulin antibodies is elevated in an esophageal secretion sample obtained from a subject, diagnosing the subject with active EoE when the level of one or more immunoglobulin antibodies in the sample is elevated above a pre-determined cut-off value and diagnosing the subject with inactive EoE when the level of one or more immunoglobulin antibodies level in the sample is below a pre-determined cut-off value; and treating the subject diagnosed with active EoE.

The present application relates to a kind of double-flow robust signal classification method and equipment based on granulocyte geometric rectification and depth feature complementation.The method constructs double-flow feature extraction architecture: on the one hand, introduce granulocyte calculation theory to process IQ view, by adaptively dividing signal sample into several hyperspheres, extract purity, density and reliability and other macroscopic geometric features, enhance the anti-noise robustness of model under low signal-to-noise ratio from coarse-grained level;On the other hand, use the mixed deep network formed by Transform and LSTM to process AP view, combine global attention and local time series modeling capability, extract deep semantic features.In addition, introduce fuzzy regularization term to sharpen the constraint on output probability distribution, improve the discrimination confidence of easily confused classes.Through the organic integration of macroscopic geometric view, microscopic space-time view and fuzzy regularization, the present application effectively breaks through the performance bottleneck of signal classification under complex communication environment.

This application relates to a method for analyzing the relationship between gut microbiota and emotional symptoms in IBS patients, comprising: determining a causal relationship between gut microbiota and emotional symptoms in IBS patients; determining that emotional symptoms are caused by a decrease in the abundance of *A. shahii* in the gut microbiota; determining that emotional symptoms are caused by a decrease in indole produced by gut microbiota metabolism, and that the decrease in indole is caused by a decrease in the abundance of *A. shahii*; determining that emotional symptoms are caused by a decrease in TnAse produced by the gut microbiota, and that the decrease in TnAse is caused by a decrease in the abundance of *A. shahii*, and the decrease in indole is caused by a decrease in TnAse; determining that emotional symptoms are caused by a decrease in AhR signaling in vDG in IBS patients, and that the decrease in AhR signaling is caused by a decrease in indole; determining that emotional symptoms are caused by a decrease in vDG granulocyte activity, and that the decrease in vDG granulocyte activity is caused by a decrease in AhR signaling, thereby obtaining analytical results showing that gut microbiota regulates emotional symptoms through the *A. shahii*-TnAse-indole-AhR-vDG signaling pathway.

The application discloses an incomplete multi-omics cancer subtype identification method, system, device and medium, and belongs to the technical field of bioinformatics and artificial intelligence. The method comprises the following steps: incomplete multi-omics data acquisition and preprocessing; constructing an entry-level observation mask matrix and a view availability mask matrix; constructing a feature module in the omics based on a granulocyte division; extracting a module-level skeleton representation; recovering an entry-level missing value based on the skeleton structure; constructing a multi-expert skeleton recovery integrated result; constructing a central feature matrix of the feature module; constructing a cross-omics consensus structure space; performing a mask-aware skeleton consensus alignment; performing adaptive view weighting based on structure reliability; performing sample-level mask-aware fusion; and outputting a cancer subtype clustering result. The application provides reliable technical support for cancer typing research, patient stratification analysis, prognosis evaluation and precision medicine auxiliary decision-making.

This invention discloses a detection kit and method for abnormal lymphocytes, myeloid blast cells, and acute promyelocytic leukemia. The detection kit includes a first reagent and a second reagent. The first reagent includes a hemolysin and a staining agent. The second reagent includes a hemolysin, a staining agent, and an antibody treatment agent, including CD13 and CD34 antibody treatment agents. The hemolysin, based on a total volume of 1L, includes the following components: 0.1-10g castor oil polyoxyethylene ether nonionic surfactant, 0.01-10g cationic surfactant, 0.5-15g buffer, 0.01-8g preservative, with the remainder being water. The pH value of the hemolysin is 5-9. The staining agent, based on a total volume of 1L, includes the following components: 0.001-0.2g nucleic acid dye, with the remainder being a solvent. The detection method includes: obtaining a blood sample to be tested, preparing a first sample, testing the first sample, preparing a second sample, and testing the second sample. This invention can accurately detect abnormal lymphocytes, myeloid blast cells, and diagnose acute promyelocytic leukemia.

This invention relates to the field of biomedical technology, and provides CD177. + Application of granulocyte subsets in the preparation of kits for the auxiliary diagnosis of tuberculosis. The CD177... + Granulocyte subsets include CD177 + Neutrophils and CD177 + Low-density granulocytes; the kit detects CD177. + The proportion of neutrophil-positive cells and CD177 + The mean fluorescence intensity of low-density granulocytes aids in the diagnosis of tuberculosis. This invention utilizes CD177. + Granulocyte subsets, as biomarkers, play an important role in auxiliary diagnosis, disease activity monitoring, and improving diagnostic efficiency. Based on CD177... + The proportion of neutrophil-positive cells, CD177 + By using the mean fluorescence intensity of low-density granulocytes, the ratio of neutrophils to lymphocytes, the ratio of platelets to lymphocytes, and the systemic inflammatory index, a predictive model for the auxiliary diagnosis of tuberculosis can be constructed. This model can more accurately identify true tuberculosis patients and effectively exclude non-patients, reducing the risk of misdiagnosis and missed diagnosis.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.

The application belongs to the technical field of biological medicine, and particularly relates to a neutrophil biomimetic vesicle nano preparation for targeting colorectal cancer and a preparation method and application thereof. The application provides a neutrophil biomimetic vesicle nano preparation for targeting colorectal cancer, wherein the neutrophil biomimetic vesicle nano preparation comprises neutrophil biomimetic vesicles, tumor-targeting peptides and photosensitizers; the tumor-targeting peptides are modified on the surface of the neutrophil biomimetic vesicles; the photosensitizers are loaded in the neutrophil biomimetic vesicles; and the photosensitizers comprise chlorin e6. The neutrophil biomimetic vesicle nano preparation has a stable core-shell structure, can effectively protect the activity of the photosensitizers, prevent leakage and aggregation quenching of the photosensitizers, and specifically enriches the photosensitizers (Ce6) in tumor cells, so that targeted delivery of the drug is realized. The problems of poor targeting of the existing photosensitizers, large toxic and side effects, short circulation time of the synthetic nano carriers, poor biocompatibility and the like are solved.

A recombinant nucleic acid molecule is encoded at least by an ORF to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one first hairpin loop structure, at least one second hairpin loop structure and a first promoter. The first and second hairpin loop structure regulates an amount of Granulocyte monocyte colony stimulating factor (GMCSF) cytokine and Interleukin 6 (IL6) cytokine, respectively. The first hairpin loop structure is formed by at least two first short hairpin RNA sequences and at least one microRNA30 sequence. The second hairpin loop structure is formed by at least two second short hairpin RNA sequences and at least one microRNA30 sequence. The first promoter is disposed upstream of the first and second hairpin loop structure.